WENFEI GE1,#, SHIYAN SONG1,#, XIAOCHEN QI1,#, FENG CHEN1,#, XIANGYU CHE1, YONGHAO SUN1, JIN WANG1, XIAOWEI LI2, NANA LIU3, QIFEI WANG1,*, GUANGZHEN WU1,*
Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942
- 22 May 2023
Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More >
Graphic Abstract
Login
Register
